Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 6,123 matching trials from the live ClinicalTrials.gov search.
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
938 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Conditions
Chronic Kidney Disease, Diabetes
Interventions
CKD Awareness, Referrals, Education, and Support (CARES), Attention control
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cardiovascular Diseases, Heart Diseases, Diabetes Mellitus, Type 2, Coronary Disease
Interventions
Problem Solving Skills
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Fatty Liver
Interventions
VSL#3
Drug
Lead sponsor
VSL Pharmaceuticals
Industry
Eligibility
45 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Type 2 Diabetes
Interventions
Acipimox, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
2 Years and older
Enrollment
7,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
65
States / cities
Phoenix, Arizona • Palo Alto, California • Pasadena, California + 51 more
Conditions
Partially Edentulous Mandible, Type 2 Diabetes
Interventions
dental implant and modified dental implant
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Diego, La Jolla, California • Gainesville, Florida
Conditions
Type 2 Diabetes
Interventions
Scorecard, Control
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
40 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • San Antonio, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

NCT05925920
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
ENT-03, Placebo
Drug
Lead sponsor
Metabolics Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Completed Not applicable Interventional Results available

My Diabetes, My Community

NCT04970810
Conditions
Type 2 Diabetes
Interventions
My Diabetes Goal, My Diabetes Goal + CommunityRx
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
60 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Heart Failure, Type 2 Diabetes Mellitus
Interventions
Beta-hydroxy-butyrate
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Interventions
Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo
Combination Product · Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
45
States / cities
Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more
Conditions
Type II Diabetes Mellitus
Interventions
CX11, Placebo
Drug · Other
Lead sponsor
Corxel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Cerritos, California + 28 more
Recruiting No phase listed Observational Accepts healthy volunteers

Human Observatory Study

NCT07646782
Conditions
Aging, Mortality, All-cause Mortality, Life Expectancy, Cardiovascular Diseases, Neoplasms, Cognitive Dysfunction, Metabolic Syndrome, Frailty, Musculoskeletal Disease, Neurodegenerative Disease, Dementia, Activities of Daily Living, Health Related Quality of Life, Environmental Exposure, Occupational Diseases, Health Equity, Social Determinants of Health, Physical Disability
Interventions
Multi-Domain Ecological and Clinical Data Linkage
Other
Lead sponsor
Longevity Metrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2099
U.S. locations
1
States / cities
Boulder, Colorado
Active, not recruiting Phase 4 Interventional

Dapagliflozin Plus Pioglitazone in T1DM

NCT03878459
Conditions
Type 1 Diabetes Mellitus
Interventions
Pioglitazone 45 mg, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Diabetic Nephropathy
Interventions
Nidufexor, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Miami Lakes, Florida • Albany, New York • Norman, Oklahoma + 2 more
Withdrawn Not applicable Interventional

Diabetes Prevention and Education

NCT05769127
Conditions
Diabetes, Pre Diabetes, Fatty Liver, Body Weight Changes
Interventions
Diabetes Prevention Program (DPP), Diabetes Self-Management Training (DSMT)
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Interventions
Clopidogrel, Clopidogrel active metabolite
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Hypercholesterolemia, Familial Hypercholesterolemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 45 more
Conditions
Diabetes Mellitus Type 2
Interventions
placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Buena Park, California + 67 more